Literature DB >> 2899265

Cibenzoline and hypoglycaemia.

B A Gachot, M Bezier, J F Cherrier, J Daubeze.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2899265     DOI： 10.1016/s0140-6736(88)92570-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Block of pancreatic ATP-sensitive K+ channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline.

Authors:  A Ishida-Takahashi; M Horie; Y Tsuura; H Ishida; T Ai; S Sasayama
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 3.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

4.  Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.

Authors:  Y Tabuchi; H Yashiro; S Hoshina; S Asano; N Takeguchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells.

Authors:  M Kakei; M Nakazaki; T Kamisaki; I Nagayama; Y Fukamachi; H Tanaka
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Cibenzoline inhibits diazoxide- and 2,4-dinitrophenol-activated ATP-sensitive K+ channels in guinea-pig ventricular cells.

Authors:  T Sato; B Wu; S Nakamura; T Kiyosue; M Arita
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 7.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.